This clinical trial is focused on studying the effects of a medication called Ozanimod on individuals with Crohn’s Disease, which is a condition that causes inflammation in the digestive tract, leading to symptoms like abdominal pain and diarrhea. The study aims to understand the long-term safety and effectiveness of Ozanimod for people who have moderate to severe forms of this disease. Ozanimod is taken orally in the form of a hard capsule.
Participants in the study will receive Ozanimod and will be monitored over a period to observe how their symptoms change. The study will look at various aspects, such as the reduction in abdominal pain and stool frequency, and improvements in the condition of the digestive tract. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Ozanimod.
The study is designed to gather information over several years, providing insights into how Ozanimod can help manage Crohn’s Disease in the long term. Participants will be regularly assessed to track their progress and any changes in their condition. This research is important for developing better treatments for those living with Crohn’s Disease.
Bulgaria 
Croatia 
Czechia 
France 
Germany 
Hungary 
Ireland 
Italy 
Latvia 
Poland 
Portugal 
Romania 
Slovakia 
Spain 
The Netherlands 
